Aptar Pharma Introduces Collaborative System-Level Framework to Advance Injectable Drug Delivery Development Aptar Pharma, a global leader in drug delivery, dosing, protection technologies, and pharmaceutical services, has announced the launch of a new collaborative system-level framework designed to support the…
Mirador Therapeutics Expands Precision Immunology Pipeline Through Global Licensing Agreement for KP-301 Mirador Therapeutics, Inc., a clinical-stage biotechnology company focused on developing precision medicines for immune-mediated inflammatory and fibrotic diseases, has announced a significant expansion of its research and development…
TruTechnologies Unveils New Brand Identity as It Advances Real-Time Clinical Trial Innovation TruTechnologies, a clinical trial software company specializing in real-time visibility into trial execution at the point of care, has introduced a refreshed corporate brand identity alongside the launch…
Zoetis Launches Lenivia® in Europe and Canada to Provide Long-Acting Osteoarthritis Pain Relief for Dogs Zoetis Inc., a global leader in animal health, has announced the commercial launch of Lenivia® (izenivetmab injection) across Canada and European Union member states. The…
BioXcellerator Joins Congressional Veterans Care Forum to Advance Dialogue on Evidence-Based Regenerative Medicine BioXcellerator, a global provider of evidence-based regenerative medicine therapies, has announced that its Co-Founder and Chief Executive Officer, Eric Stoffers, will participate in the upcoming Congressional Veterans…
Alkermes Reports Sustained Long-Term Benefits of Alixorexton in Narcolepsy Types 1 and 2 Alkermes plc has announced encouraging interim results from the ongoing long-term extension (LTE) study evaluating alixorexton, its investigational oral orexin 2 receptor (OX2R) agonist, in adults with…
PADCEV® Combination Approved for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility Pfizer Inc. and Astellas Pharma Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv) in combination with the PD-1 inhibitor Keytruda® (pembrolizumab)…
OneLegacy Launches Western U.S.’s First Organ Procurement Organization-Based Ex Vivo Lung Perfusion Program to Expand Access to Lung Transplantation OneLegacy, the nonprofit organ procurement organization (OPO) serving Southern California, has announced the launch of the first in-house Ex Vivo Lung…
Auragens Named Stem Cell Treatment Center of the Year 2026, Earning Back-to-Back Recognition for Leadership in Regenerative Medicine Auragens has announced that it has been recognized as Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, marking…
Retham Technologies Launches Next-Generation Cryoplatelets to Improve Platelet Research and Laboratory Testing Retham Technologies, Inc. has announced the commercial launch of Retham Cryoplatelets™, a next-generation functional platelet product developed to address one of the most persistent challenges in biomedical research—the…
MEDIPOST Treats First U.S. Patient in Phase III Trial of Investigational Stem Cell Therapy for Knee Osteoarthritis MEDIPOST Inc., a biotechnology company specializing in the development of allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, has announced…
Leo Cancer Care Secures $65 Million Series D Funding to Expand Upright Cancer Imaging and Treatment Platform Leo Cancer Care has announced the successful completion of an oversubscribed $65 million Series D financing round, providing the company with significant new…